[go: up one dir, main page]

CA2387123A1 - Utilisation de thienopyrimidines - Google Patents

Utilisation de thienopyrimidines Download PDF

Info

Publication number
CA2387123A1
CA2387123A1 CA002387123A CA2387123A CA2387123A1 CA 2387123 A1 CA2387123 A1 CA 2387123A1 CA 002387123 A CA002387123 A CA 002387123A CA 2387123 A CA2387123 A CA 2387123A CA 2387123 A1 CA2387123 A1 CA 2387123A1
Authority
CA
Canada
Prior art keywords
pyrimidin
acid
thieno
benzo
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002387123A
Other languages
English (en)
Inventor
Rochus Jonas
Volker Eiermann
Sabine Bernotat-Danielowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2387123A1 publication Critical patent/CA2387123A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Thiénopyrimidines de formule (I), ainsi que des sels et/ou solvates acceptables sur le plan physiologique desdites substances. Dans la formule (I), R?1¿, R?2¿ et X possèdent la signification figurant dans la revendication 1. Lesdites substances sont utilisées pour préparer un médicament destiné à traiter l'angine de poitrine, l'hypertension artérielle, l'hypertension pulmonaire, l'insuffisance cardiaque congestive, l'athérosclérose, la réduction du passage dans les vaisseaux cardiaques, les maladies vasculaires périphériques, l'accident vasculaire cérébral, la bronchite, l'asthme allergique, l'asthme chronique, la rhinite allergique, le glaucome, le syndrome du colon irritable, les tumeurs, l'insuffisance rénale, la cirrhose du foie et l'impuissance féminine.
CA002387123A 1999-09-14 2000-08-24 Utilisation de thienopyrimidines Abandoned CA2387123A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19943815A DE19943815A1 (de) 1999-09-14 1999-09-14 Verwendung von Thienopyrimidinen
DE19943815.3 1999-09-14
PCT/EP2000/008258 WO2001019369A1 (fr) 1999-09-14 2000-08-24 Utilisation de thiénopyrimidines

Publications (1)

Publication Number Publication Date
CA2387123A1 true CA2387123A1 (fr) 2001-03-22

Family

ID=7921854

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002387123A Abandoned CA2387123A1 (fr) 1999-09-14 2000-08-24 Utilisation de thienopyrimidines

Country Status (18)

Country Link
EP (1) EP1212062A1 (fr)
JP (1) JP2003509370A (fr)
KR (1) KR20020026011A (fr)
CN (1) CN1377271A (fr)
AR (1) AR025645A1 (fr)
AU (1) AU6703200A (fr)
BR (1) BR0013957A (fr)
CA (1) CA2387123A1 (fr)
CZ (1) CZ2002818A3 (fr)
DE (1) DE19943815A1 (fr)
HU (1) HUP0202614A3 (fr)
MX (1) MXPA02002746A (fr)
NO (1) NO20021234D0 (fr)
PL (1) PL353343A1 (fr)
RU (1) RU2002107441A (fr)
SK (1) SK3322002A3 (fr)
WO (1) WO2001019369A1 (fr)
ZA (1) ZA200202868B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1347762A2 (fr) * 2000-12-19 2003-10-01 MERCK PATENT GmbH Formulation pharmaceutique contenant des thienopyrimidines et des antithrombotiques, des inhibiteurs calciques, des prostaglandines ou des derives de prostaglandine (2)
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
HU228446B1 (en) * 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
DE19819023A1 (de) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
US5948911A (en) * 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives
WO2000059912A1 (fr) * 1999-03-30 2000-10-12 Nippon Soda Co., Ltd. Composes de thienopyrimidine et leurs sels, et procede de preparation desdits composes et sels

Also Published As

Publication number Publication date
BR0013957A (pt) 2002-05-21
CZ2002818A3 (cs) 2002-06-12
WO2001019369A1 (fr) 2001-03-22
CN1377271A (zh) 2002-10-30
HUP0202614A3 (en) 2004-11-29
ZA200202868B (en) 2003-11-26
SK3322002A3 (en) 2002-07-02
PL353343A1 (en) 2003-11-17
DE19943815A1 (de) 2001-03-15
AR025645A1 (es) 2002-12-04
MXPA02002746A (es) 2002-10-23
JP2003509370A (ja) 2003-03-11
NO20021234L (no) 2002-03-13
AU6703200A (en) 2001-04-17
HUP0202614A2 (hu) 2002-12-28
RU2002107441A (ru) 2003-11-20
EP1212062A1 (fr) 2002-06-12
NO20021234D0 (no) 2002-03-13
KR20020026011A (ko) 2002-04-04

Similar Documents

Publication Publication Date Title
CA2311922C (fr) Thienopyrimidines
US20040034040A1 (en) Use of thienopyrimidines
US6787548B1 (en) Thienopyrimidines as phosphodiesterase inhibitors
CA2328280C (fr) Thienopyrimidines
US6777419B1 (en) Pyrazolo [4,3-d]pyrimidines
US20040077664A1 (en) Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates
US20040023990A1 (en) Use of pyrazolo[4,3-d]pyrimidines
US20040023991A1 (en) Use of pyrazolo[4,3-d]pyrimidines
AU2001237379B2 (en) Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction
CA2387123A1 (fr) Utilisation de thienopyrimidines
US6780867B2 (en) Thienopyrimidines
CA2387520A1 (fr) Derives d'amine
MXPA00010415A (en) Condensed thienopyrimidines with phosphodiesterase-v inhibiting action

Legal Events

Date Code Title Description
FZDE Discontinued